Prima BioMed Ltd (IMMP) vs Karyopharm Therapeutics Inc. (KPTI)

Prima BioMed Ltd and Karyopharm Therapeutics Inc. are both Biotechnology companies. Prima BioMed Ltd and Karyopharm Therapeutics Inc. are of similar size ($39.2M and $38.5M). Across the 10 metrics below, Prima BioMed Ltd leads on 6 and Karyopharm Therapeutics Inc. on 4.

Valuation

Metric IMMP KPTI Biotechnology median
P/E n/m n/m 7.88
P/S n/m 0.32 11.47
P/B 0.49 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 1.58 10.73
Earnings yield (40.42%) (874.99%) (28.84%)
Free cash flow yield (181.72%) (139.70%) (23.03%)

Profitability

Metric IMMP KPTI Biotechnology median
Gross margin — 95.89% 65.16%
Operating margin — (56.17%) 0.00%
Net margin — (153.28%) 0.00%
Free cash flow margin 0.00% (44.57%) 0.00%
Return on equity 0.00% 78.98% (57.72%)
Return on assets 0.00% (207.90%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMMP KPTI Biotechnology median
Revenue growth (TTM) — 6.81% 5.64%
EPS growth (last fiscal year) (37.04%) (98.37%) —
Revenue growth, 5-year CAGR 40.79% 6.21% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMMP KPTI Biotechnology median
Debt to equity 0.01 (0.76) 0.00
Current ratio 2.97 0.79 4.73
Net debt to EBITDA 0.92 (2.03) 0.96

Dividend

Metric IMMP KPTI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IMMP KPTI Biotechnology median
Market cap 38.48m 39.24m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack